Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
br Neurodegenerative diseases definition and categories Dise
2021-06-25

Neurodegenerative diseases: definition and categories Diseases that their progression is dependent on the formation of protein aggregates, are generally identified as protein aggregation diseases. Most common among them is neurodegenerative diseases, in which the protein abnormally i thought abou
-
br Introduction Maintaining the normal function
2021-06-25

Introduction Maintaining the normal function of fetal trophoblasts is essential for a successful pregnancy. Preeclampsia (PE), a pregnancy-specific disorder, is often associated with excessive trophoblast cell apoptosis and superficial trophoblast invasion leading to insufficient spiral artery re
-
Darifenacin HBr sale Increased leukocyte trafficking and inf
2021-06-25

Increased leukocyte trafficking and infiltration of the vascular wall are thought to provide a key stimulus for SMC activation and subsequent neointima formation in response to vascular injury [19], [20]. The essential trigger regulating the accumulation of leukocytes in the vessel wall is the upreg
-
Our results demonstrate that pt PGE in addition
2021-06-25

Our results demonstrate that 17-pt-PGE2 - in addition to its described effects on EP1 and EP3 receptors - also acts as an EP4 agonist and thereby enhances vascular barrier function. Materials and methods Results Discussion In this study we demonstrate that the purported EP1/EP3 receptor ag
-
br Materials and methods br Results br Discussion In rodent
2021-06-25

Materials and methods Results Discussion In rodent species, CYP2E1 and CYP2B have been implicated in CCl4 metabolism. In this study, we used expressed human CYP2E1 to show that this enzyme is a high-affinity catalyst responsible for low-dose CCl4 metabolism. Studies employing an inhibitory
-
br Results br Discussion The origin and fate
2021-06-25

Results Discussion The origin and fate of Tfh cells has been intensely studied since their first description 14 years ago (Breitfeld et al., 2000, Schaerli et al., 2000). Although mice engineered to report BCL6 (Kitano et al., 2011, Liu et al., 2012) and interleukin-21 (IL-21) (Lüthje et al.,
-
br Acknowledgements E B was supported
2021-06-25

Acknowledgements E.B. was supported by grant 16-34-60213 mol_a_dk from the Russian Foundation for Basic Research (RFBR). R.S. and A.V. were supported by grant of the President of Russian FederationMK-4253.2018.4. The work was performed according to the Russian Government Program of Competitive Gr
-
In all available E E structures the RING type domain
2021-06-25

In all available E2:E3 structures, the RING-type domain binds the E2 on a surface that is remote from the active site Cys (and therefore from the ubiquitin thioester) (Fig. 2). The non-contiguous E3-binding and active sites on the E2 imply that the role played by a RING to facilitate ubiquitin trans
-
Intriguingly one E residue may serve as a molecular
2021-06-25

Intriguingly, one E2 residue may serve as a molecular ‘gate’ to allow the C-terminus of ubiquitin to access the closed E2~Ub conformations favorable for ubiquitin transfer. This residue, Asp87 in UbcH5 family members, resides on one side of the opening that leads to the active site Cys (Fig. 4D). In
-
Valproic acid VPA is a first line treatment for
2021-06-25

Valproic LY3039478 (VPA) is a first-line treatment for epilepsy and bipolar disorder, although its therapeutic mechanism of action is not fully understood. Considerable evidence suggests that VPA can act through the GABAergic system, NMDA receptors, and/or sodium channels (for review, see Löscher,
-
A recent study revealed that in human glioma
2021-06-25

A recent study revealed that in human glioma cells, DNA-PKcs interacted with the regulatory γ subunit of AMPK and positively regulated AMPK phosphorylation and activation under glucose-deprived conditions. This suggested that DNA-PK is an important regulator of AMPK activation in response to energy
-
DGK type I http www
2021-06-25

DGKη1 (type II DGK) has a separated catalytic domain [10], [13], whereas the domains of DGKα, ε and ζ are not split [1], [2], [3], [4], [5]. Therefore, the structural difference may cause the distinct affinity for DG among these isozymes. Because other type II DGKs (η2, δ1, δ2 and κ) also have the s
-
Moreover maintaining the pyrimidine pool
2021-06-25

Moreover, maintaining the pyrimidine pool is not the only important role played by DHODHs. In Toxoplasma gondii, for instance, DHODH plays a second essential function [38] possibly coupled to the mitochondrial respiratory activity, where it replenishes ubiquinol levels and prevents reactive oxygen s
-
Cultured cells or mouse lung tissues were harvested and
2021-06-24

Cultured cells or mouse lung tissues were harvested and lysed in Radio-Immunoprecipitation Assay (RIPA) buffer (0.05 mol/l Tris–HCl pH 7.4, 0.15 mol/l NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mmol/l ethylenediamine tetraacetic SJB3-019A mg (EDTA), 1 mmol/l phenylmethylsulfonyl fuoride, 1 μg/ml apro
-
Interestingly some drugs have been shown to be effective in
2021-06-24

Interestingly, some drugs have been shown to be effective in the regulation of cytokine production (such as IL-2, IL-10, IL-27, IL-35, IL-37 and transforming growth factor-β, TGF-β) and, therefore, having a key role in the management of certain inflammatory-based clinical conditions (Banchereau et a
15014 records 648/1001 page Previous Next First page 上5页 646647648649650 下5页 Last page